title: A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
abstract: Cabergoline and quinagolide, two new dopamine agonist drugs with long-lasting activity, are currently under investigation for the treatment of hyperprolactinemia. At present, studies comparing these drugs for tolerability and efficacy in the same patients are lacking. It was our aim to make such a comparison in an open randomized cross-over trial. Cabergoline (0.5 mg twice weekly) and quinagolide (75 micrograms once daily) were given orally. Each drug was administered for 12 weeks. Treatment with the second drug was started after the recurrence of hyperprolactinemia. Twelve women with hyperprolactinemia due to idiopathic disease (n = 6), microprolactinoma (n = 5) or postsurgical empty sella (n = 1) were evaluated. Six women were amenorrheic and 6 were oligomenorrheic. Ten had spontaneous or provoked galactorrhea. Baseline characteristics (age, clinical signs and PRL levels) of patients initially allocated to the two treatment groups were similar. Nine patients completed both treatment cycles and PRL levels were lower under cabergoline (10.7 +/- 3.7 micrograms/L) than under quinagolide (25.0 +/- 7.7 micrograms/L; p < 0.05). One patient discontinued cabergoline because of dryness of the eyes after having completed the quinagolide cycle and 2 patients initially treated with cabergoline discontinued quinagolide because of gastrointestinal symptoms. After completion of the first treatment cycle, the time of recurrence of hyperprolactinemia was significantly longer after cabergoline (14 +/- 7 weeks) than after quinagolide (5 +/- 1 weeks; p < 0.05). At week 12, normal PRL levels (< 20 micrograms/L) were observed in 10 and 6 women during cabergoline and quinagolide, respectively. Only one case was resistant to both drugs. The clinical effects of the two treatments were similar.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: DISEM, Cattedra di Endocrinologia, Università di Genova, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Giusti
authors.forename: E
authors.initials: E
authors.lastname: Porcella
authors.forename: A
authors.initials: A
authors.lastname: Carraro
authors.forename: M
authors.initials: M
authors.lastname: Cuttica
authors.forename: S
authors.initials: S
authors.lastname: Valenti
authors.forename: G
authors.initials: G
authors.lastname: Giordano
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000634:Aminoquinolines / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D000077465:Cabergoline; D015259:Dopamine Agents / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D011388:Prolactin / Q000097:blood / Q000378:metabolism
chemical_list: D000634:Aminoquinolines; D015259:Dopamine Agents; D004873:Ergolines; C046650:quinagolide; D011388:Prolactin; D000077465:Cabergoline